Delving into the Latest Updates on Tianjin Hengrui Pharmaceutical Co., Ltd with Synapse

Overview

Basic Info

Introduction

Tianjin Hengrui Pharmaceuticals Co., Ltd. operates as a wholly-owned subsidiary of Hengrui Medicine, founded in November 2020. Its mission is to build an integrated platform dedicated to the research and development transformation of oncology diagnostic and therapeutic drugs.

Tags

Neoplasms

Urogenital Diseases

Digestive System Disorders

Small molecule drug

Chemical drugs

Diagnostic radiopharmaceuticals

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Infectious Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	2
Chemical drugs	2
Diagnostic radiopharmaceuticals	2
Peptide Conjugate Radionuclide	1
Therapeutic radiopharmaceuticals	1

Top 5 Target	Count

PSMA(Prostate-specific membrane antigen)	2
SSTR(Somatostatin receptor)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

2

1

Phase 1

Phase 2

1

Phase 3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

68Ga-Edotreotide ( SSTR )	Gastro-Enteropancreatic Neuroendocrine Tumor More	Phase 3
HRS-4357 ( PSMA )	PSMA-Positive Prostatic Cancer More	IND Approval
HRS-9815 ( PSMA )	PSMA-Positive Prostatic Cancer More	IND Approval